Capricor to Present Phase 3 HOPE-3 DMD Findings, Files CSR for FDA BLA Review
Capricor’s Phase 3 HOPE-3 results for Deramiocel in Duchenne muscular dystrophy were selected for a late-breaking oral presentation at the MDA conference on March 11, 2026. The company submitted the HOPE-3 clinical study report to the FDA to address its Complete Response Letter and advance its Biologics License Application review.
1. MDA Conference Presentation
Capricor’s Phase 3 HOPE-3 study of Deramiocel in Duchenne muscular dystrophy has been selected for a late-breaking oral presentation at the Muscular Dystrophy Association Clinical and Scientific Conference on March 11, 2026 at 2:45 p.m. ET. Craig McDonald, M.D., the National Principal Investigator of HOPE-3, will discuss musculoskeletal and cardiac benefits observed in the trial’s 106 participants.
2. FDA Submission and Regulatory Context
Following prior FDA feedback, Capricor submitted the HOPE-3 clinical study report to address items outlined in the Complete Response Letter. This submission supports the ongoing Biologics License Application review for Deramiocel and may trigger assignment of a new Prescription Drug User Fee Act target action date.
3. Potential Impact and Next Steps
The late-breaking presentation and FDA report submission strengthen the clinical evidence package for Deramiocel, reinforcing its potential as the first cell-based therapy for DMD. A favorable FDA decision could offer a new treatment option to approximately 15,000 affected individuals in the U.S. and qualify Capricor for a Priority Review Voucher.